Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley fever

Rift Valley Fever virus (RVFV) causes recurrent outbreaks of acute life-threatening human and livestock illness in Africa and the Arabian Peninsula. No licensed vaccines are currently available for humans and those widely used in livestock have major safety concerns. A ‘One Health’ vaccine development approach, in which the same vaccine is co-developed for multiple susceptible species, is an attractive strategy for RVFV. Here, we utilized a replication-deficient chimpanzee adenovirus vaccine platform with an established human and livestock safety profile, ChAdOx1, to develop a vaccine for use against RVFV in both livestock and humans. We show that single-dose immunization with ChAdOx1-GnGc vaccine, encoding RVFV envelope glycoproteins, elicits high-titre RVFV-neutralizing antibody and provides solid protection against RVFV challenge in the most susceptible natural target species of the virus-sheep, goats and cattle. In addition we demonstrate induction of RVFV-neutralizing antibody by ChAdOx1-GnGc vaccination in dromedary camels, further illustrating the potency of replication-deficient chimpanzee adenovirus vaccine platforms. Thus, ChAdOx1-GnGc warrants evaluation in human clinical trials and could potentially address the unmet human and livestock vaccine needs.

Bibliographic Details

Main Authors:	Warimwe, G.M., Gesharisha, J., Carr, B.V., Otieno, S., Otingah, K., Wright, D., Charleston, B., Okoth, Edward A., Elena, L.G., Lorenzo, G., Ayman, E.B., Alharbi, N.K., Al-Dubaib, M.A., Brun, A., Gilbert, S.C., Nene, Vishvanath, Hill, A.V.S.
Format:	Journal Article biblioteca
Language:	English
Published:	Springer 2016-02-05
Subjects:	animal diseases, vaccines, zoonoses,
Online Access:	https://hdl.handle.net/10568/71057 https://doi.org/10.1038/srep20617
Tags:	Add Tag No Tags, Be the first to tag this record!